Market Place
Sourcing Support
Novartis Presents Latest Phase III Fabhalta Data
25 May 2024 //
PRESS RELEASE
Novartis Fabhalta® C3G Phase 3: 35.1% Proteinuria Reduction Vs Placebo
25 May 2024 //
GLOBENEWSWIRE
Novartis touts trial win, nabs priority review for Fabhalta
15 Apr 2024 //
FIERCE PHARMA
Novartis Fabhalta® Reduces IgAN Proteinuria By 38.3% Vs Placebo
15 Apr 2024 //
GLOBENEWSWIRE
Novartis` Fabhalta wins EU panel`s favour for rare blood disorder
23 Mar 2024 //
PRESS RELEASE
FABHALTA Now Available from Onco360 for the Treatment of PNH
20 Dec 2023 //
BUSINESSWIRE
Novartis shows strong Fabhalta results in another blood disorder
12 Dec 2023 //
FIERCE PHARMA
Novartis receives FDA approval for Fabhalta® (iptacopan) for adults with PNH
06 Dec 2023 //
PR NEWSWIRE
Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
20 Nov 2023 //
GLOBENEWSWIRE
Novartis’ iptacopan has ‘faultless’ performance in phase 3
02 Oct 2023 //
FIERCE BIOTECH
Novartis PhIII APPOINT-PNH trial shows Invg oral monotherapy iptacopan
26 Apr 2023 //
GLOBENEWSWIRE
Novartis touts new budding disease med as it battles AstraZeneca
14 Dec 2022 //
FIERCEBIOTECH
Novartis` iptacopan meets PhIII test in fight against rare blood disease
09 Dec 2022 //
FIERCEBIOTECH
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix
22 Nov 2022 //
PRNEWSWIRE
Novartis` iptacopan superior to injectable anti-C5 therapies in PNH study
27 Oct 2022 //
NOVARTIS
Novartis` $3B prospect beats AstraZeneca blockbuster in phase 3
25 Oct 2022 //
FIERCEBIOTECH
Novartis’ iptacopan meets primary endpoints in phase II study
08 Nov 2021 //
PHARMABIZ
Novartis’ iptacopan hits endpoints in mid-stage study
05 Nov 2021 //
PHARMATIMES
Novartis iptacopan meets primary in Ph II study in rare kidney disease C3
04 Nov 2021 //
PRNEWSWIRE
Novartis’ iptacopan scores positive results in rare blood disorder PNH
14 Jun 2021 //
PMLIVE
Novartis gets FDA Breakthrough Therapy tag for experimental iptacopan
16 Dec 2020 //
REUTERS
Novartis’ iptacopan reduces proteinuria in rare renal disease trial
27 Oct 2020 //
CLINICALTRIALSARENA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.